COBRA PzF NanoCoated Coronary Stent (NCS)

Designed with
Healing in mind

The revolutionary COBRA PzF NCS is a new nanocoated, non drug-eluting stent that allows physicians to safely and effectively treat their patients who may benefit from a short, minimum 1-month DAPT requirement.1

Designed with Healing in Mind

The revolutionary COBRA PzF NCS is a new nanocoated, non drug-eluting stent that allows physicians to safely and effectively treat their patients who may benefit from a short, minimum 1-month DAPT requirement.1

Exceptional Safety & Efficacy

In the FDA PzF SHIELD IDE trial, COBRA PzF NCS demonstrated an excellent safety profile with minimum 1-month DAPT.1,2

Several additional studies demonstrated low rates of stent thrombosis, zero late stent thrombosis with low DAPT.

Learn About COBRA REDUCE IDE 14-Day DAPT Trial
At 270 Days

0%

Stent Thrombosis2

4.6%

TLR‡2

1

Month DAPT1
minimum requirement

COBRA PzF NCS indications include patients with diabetes mellitus
Learn About COBRA REDUCE IDE 14-Day DAPT Trial

Polyzene-F NanoCoating
Makes the Difference

Polyzene-F is a nano-thin surface coating that has been studied extensively in the past 20+ years, demonstrating thrombo-resistant, anti-inflammatory and rapid healing effects in preclinical studies.3-7*

Polyzene-F NanoCoating Makes the Difference

Polyzene-F is a nano-thin surface coating that has been studied extensively in the past 20+ years, demonstrating thrombo-resistant, anti-inflammatory and rapid healing effects in preclinical studies.3-7*

About PzF

Optimized Stent Performance

Polyzene-F Nano-Thin Structure

Delivery System Specifications

Balloon Specifications
Catheter Specifications

Product Ordering Information

COBRA PzF NCS is approved and commercially available for purchase in the U.S. Contact a CeloNova Sales Representative today for more information.

Contact a Sales Representative
* AS DEMONSTRATED IN PRECLINICAL STUDIES.
Correlation between bench testing, animal studies and humans have not been determined.
‡ Stent thrombosis defined as ARC Definite, Probable and Possible; stent thrombosis and cTLR assessed at 270 days [95% Confidence Interval ST, 0.00%, 1.29%, cTLR, 2.45%, 7.67%]
+ For more information about the COBRA REDUCE IDE trial, please visit: clinicaltrials.gov/ct2/show/NCT02594501.
  1. Levine G, Bates E, Bittl J, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease. Circulation. 2016;134(10):e123-55.
  2. Cutlip D, Garrat K, Novack V, et al. 9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System. JACC Cardiovasc Interv. 2017;10(2):160-167.
  3. Koppara T, Sakakura K, Pacheco E, et al. Preclinical evaluation of a novel polyphosphazene surface modified stent. International Journal of Cardiology. 2016; 222:217-225.
  4. Mrowietz C, Franke R, Seyfert U, et al. Haemocompatibility of polymer-coated stainless steel stents as compared to uncoated stents. Clinical Hemorheology and Microcirculation. 2005; 32:89–103.
  5. Richter G, Stampfl U, Stampfl S, et al. A New Polymer Concept for Coating of Vascular Stents Using PTFEP (poly(bis(trifluoroethoxy)phosphazene) to Reduce Thrombogenicity and Late In-Stent Stenosis. Investigative Radiology. 2005; 40(4):210-218.
  6. Radeleff B, Thierjung H, Stampfl U, et al. Restenosis of the CYPER-Select, TAXUS-Express, and Polyzene-F NanoCoated Cobalt-Chromium Stents in the Minipig Coronary Artery Model. Cardiovasc Intervent Radiol. 2007.
  7. Tamburino C, Giacoppo D, Capodanno D, et al. The Rapid Evaluation of Vessel Healing after Angioplasty (REVEAL) trial. Interv.Cardiol. 2011; 3 (4): 451-460.